221 related articles for article (PubMed ID: 23095259)
41. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
[TBL] [Abstract][Full Text] [Related]
42. [A case of chronic inflammatory demyelinating polyradiculoneuropathy presenting recurrent attacks associated with pregnancies].
Shiraishi N; Kinoshita M; Shimizu M; Sumikura H; Fukada K
Rinsho Shinkeigaku; 2018 Feb; 58(2):127-130. PubMed ID: 29386496
[TBL] [Abstract][Full Text] [Related]
43. [Multifocal motor neuropathies with conduction block: long-term follow-up of ten patients treated with IVIg].
Cros D; Drake K
Rev Neurol (Paris); 2006 Jun; 162 Spec No 1():3S46-3S50. PubMed ID: 17075525
[TBL] [Abstract][Full Text] [Related]
44. Childhood multifocal acquired demyelinating sensory and motor neuropathy.
Wakamoto H; Chisaka A; Inoue N; Nakano N
Muscle Nerve; 2008 Jun; 37(6):790-5. PubMed ID: 18506719
[TBL] [Abstract][Full Text] [Related]
45. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update.
Nobile-Orazio E; Gallia F; Tuccillo F; Terenghi F
Curr Opin Neurol; 2010 Oct; 23(5):519-23. PubMed ID: 20689427
[TBL] [Abstract][Full Text] [Related]
46. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.
Querol L; Rojas-Garcia R; Casasnovas C; Sedano MJ; Muñoz-Blanco JL; Alberti MA; Paradas C; Sevilla T; Pardo J; Capablo JL; Sivera R; Guerrero A; Gutierrez-Rivas E; Illa I
Muscle Nerve; 2013 Dec; 48(6):870-6. PubMed ID: 23512566
[TBL] [Abstract][Full Text] [Related]
48. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
49. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
50. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
51. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Brannagan TH
Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
[TBL] [Abstract][Full Text] [Related]
52. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].
Iijima M; Koike H; Sobue G
Nihon Rinsho; 2012 Apr; 70(4):715-21. PubMed ID: 22568158
[TBL] [Abstract][Full Text] [Related]
53. Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
Kapoor M; Keh R; Compton L; Morrow S; Gosal D; Manji H; Reilly MM; Lunn MP; Lavin TM; Carr AS
J Neurol; 2021 Apr; 268(4):1485-1490. PubMed ID: 33608795
[TBL] [Abstract][Full Text] [Related]
54. Chronic relapsing multifocal sensory-motor neuropathy with conduction block.
Sharoqi IA; Sadoh DR; Koutroumanidis M; Panayiotopoulos CP
J Peripher Nerv Syst; 1998; 3(2):133-6. PubMed ID: 10959247
[TBL] [Abstract][Full Text] [Related]
55. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
Hughes RA
Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
[TBL] [Abstract][Full Text] [Related]
56. [Diagnosis and treatment of multifocal motor neuropathy (Lewis-Sumner)].
Kaji R
Rinsho Shinkeigaku; 1999 Jan; 39(1):107-9. PubMed ID: 10377829
[TBL] [Abstract][Full Text] [Related]
57. Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant?
Remiche G; Kentos A; Mavroudakis N
Acta Neurol Belg; 2010 Mar; 110(1):103-6. PubMed ID: 20514936
[TBL] [Abstract][Full Text] [Related]
58. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
59. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
60. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features.
Rajabally YA; Chavada G
Muscle Nerve; 2009 Feb; 39(2):206-20. PubMed ID: 19145651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
